Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03151148 · ClinicalTrials.gov registry record · Phase 1
Targeted Microbiome Transplant in Atopic Dermatitis
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
NCT03151148 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 54 participants.
The verdict
NCT03151148, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the safety and effectiveness of a new therapy, commensal lotion containing infection fighting bacteria, on decreasing or eliminating the infection causing bacteria found on the skin of Atopic Dermatitis (AD) patients.
Interventions
- BIOLOGICAL TMT Lotion
- DRUG Placebo Lotion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2017-09-28 |
| Est. Completion | 2019-06-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03151148
The ClinicalTrials.gov registry entry for NCT03151148 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which TMT Lotion is the first listed.
NCT03151148 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03151148 about?
NCT03151148 is a clinical study titled "Targeted Microbiome Transplant in Atopic Dermatitis". The purpose of this study is to examine the safety and effectiveness of a new therapy, commensal lotion containing infection fighting bacteria, on decreasing or eliminating the infection causing bacteria found on the skin of Atopic Dermatitis (AD) patients.
What is the current status of trial NCT03151148?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2017-09-28. Estimated completion is 2019-06-07.
What interventions are being tested in trial NCT03151148?
The interventions under investigation include: TMT Lotion (BIOLOGICAL), Placebo Lotion (DRUG).
Who is sponsoring clinical trial NCT03151148?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.